Doxepin (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Doxepin" in English language version.

refsWebsite

Global rank English rank

54nih.gov

4^th place

40doi.org

2^nd place

18semanticscholar.org

11^th place

8^th place

13books.google.com

3^rd place

5web.archive.org

1^st place

5fda.gov

447^th place

338^th place

3drugs.com

399^th place

333^rd place

2clincalc.com

3,912^th place

2,496^th place

2handle.net

102^nd place

76^th place

2springer.com

274^th place

309^th place

2unc.edu

1,538^th place

1,042^nd place

1medicinescomplete.com

low place

1in.gov.br

3,151^st place

5,932^nd place

1medicines.org.uk

3,823^rd place

2,387^th place

1archives-ouvertes.fr

1,031^st place

879^th place

1racgp.org.au

low place

1tga.gov.au

3,984^th place

2,622^nd place

1medscape.com

719^th place

636^th place

1worldcat.org

5^th place

1archive.org

6^th place

archive.org

Joint Formulary Committee (2013). British National Formulary (BNF) (65 ed.). London, UK: Pharmaceutical Press. ISBN 978-0-85711-084-8.

archives-ouvertes.fr

hal-normandie-univ.archives-ouvertes.fr

Dupuis G, Vaugeois JM (February 2020). "Les effets anti-H1 intéressants dans les insomnies de maintien : réflexion sur les intérêts comparés de la doxylamine et de la doxépine" [The interesting anti-H1 effects in maintenance insomnia: A reflection on the comparative advantages of doxylamine and doxepin]. Encephale (in French). 46 (1): 80–82. doi:10.1016/j.encep.2019.01.006. PMID 30879783. S2CID 151085176.

books.google.com

Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 469–. ISBN 978-1-4757-2085-3.
Lemke TL, Williams DA (24 January 2012). "Antidepressants". Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. pp. 604–. ISBN 978-1-60913-345-0.
Dawkins K, Manji HK, Potter WZ (20 September 1994). "Pharmacodynamics of Antidepressants". In Cutler NR, Sramek JJ, Narang PK (eds.). Pharmacodynamics and Drug Development: Perspectives in Clinical Pharmacology. John Wiley & Sons. pp. 160–. ISBN 978-0-471-95052-3.
Baumann P, Hiemke C (23 February 2012). "Central Nervous System Drugs". In Anzenbacher P, Zanger UM (eds.). Metabolism of Drugs and Other Xenobiotics. John Wiley & Sons. pp. 302–. ISBN 978-3-527-64632-6.
Nelson JS (2009). "Tricyclic and Tetracyclic Drugs". In Schatzberg AR, Nemeroff CB (eds.). The American Psychiatric Publishing Textbook of Psychopharmacology. American Psychiatric Pub. pp. 264–. ISBN 978-1-58562-309-9.
Brunton L, Chabner BA, Knollman B (14 January 2011). Goodman and Gilman's The Pharmacological Basis of Therapeutics (Twelfth ed.). McGraw Hill Professional. p. 410. ISBN 978-0-07-176939-6.
Nelson JS (10 May 2017). "Tricyclic and Tetracyclic Drugs". In Schatzberg AF, Nemeroff CB (eds.). The American Psychiatric Association Publishing Textbook of Psychopharmacology. American Psychiatric Pub. pp. 322–. ISBN 978-1-61537-122-8.
Ebadi M (31 October 2007). Desk Reference of Clinical Pharmacology, Second Edition. CRC Press. pp. 329–. ISBN 978-1-4200-4744-8.
Anthony PK, Powers A (2002). "Drugs that affect the central nervous system". In Anthony PK (ed.). Pharmacology Secrets. Elsevier Health Sciences. pp. 39–. ISBN 1-56053-470-2.
Cowen P, Harrison P, Burns T (9 August 2012). "Drugs and other physical treatment". Shorter Oxford Textbook of Psychiatry. OUP Oxford. pp. 532–. ISBN 978-0-19-162675-3.
Zhou S (6 April 2016). "Substrates of CYP2D6". Cytochrome P450 2D6: Structure, Function, Regulation and Polymorphism. CRC Press. pp. 142–. ISBN 978-1-4665-9788-4.
Index Nominum 2000: International Drug Directory. Taylor & Francis. 2000. pp. 370–. ISBN 978-3-88763-075-1.
Morton IK, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 106–. ISBN 978-94-011-4439-1.

clincalc.com

"The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
"Doxepin Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.

doi.org

Yan JH, Hubbard JW, McKay G, Korchinski ED, Midha KK (July 2002). "Absolute bioavailability and stereoselective pharmacokinetics of doxepin". Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 32 (7): 615–23. doi:10.1080/00498250210131879. PMID 12162857. S2CID 7400543.
Weber J, Siddiqui MA, Wagstaff AJ, McCormack PL (August 2010). "Low-dose doxepin: in the treatment of insomnia". CNS Drugs. 24 (8): 713–20. doi:10.2165/11200810-000000000-00000. PMID 20658801. S2CID 26739281.
Virtanen R, Scheinin M, Iisalo E (November 1980). "Single dose pharmacokinetics of doxepin in healthy volunteers". Acta Pharmacologica et Toxicologica. 47 (5): 371–6. doi:10.1111/j.1600-0773.1980.tb01575.x. PMID 7293791.
Yeung WF, Chung KF, Yung KP, Ng TH (February 2015). "Doxepin for insomnia: a systematic review of randomized placebo-controlled trials". Sleep Medicine Reviews. 19: 75–83. doi:10.1016/j.smrv.2014.06.001. PMID 25047681.
Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL (February 2017). "Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline". Journal of Clinical Sleep Medicine. 13 (2): 307–349. doi:10.5664/jcsm.6470. PMC 5263087. PMID 27998379.
Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD (July 2016). "Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians". Annals of Internal Medicine. 165 (2): 125–33. doi:10.7326/M15-2175. PMID 27136449.
De Crescenzo F, D'Alò GL, Ostinelli EG, Ciabattini M, Di Franco V, Watanabe N, et al. (July 2022). "Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis". Lancet. 400 (10347): 170–184. doi:10.1016/S0140-6736(22)00878-9. hdl:11380/1288245. PMID 35843245. S2CID 250536370.
Dupuis G, Vaugeois JM (February 2020). "Les effets anti-H1 intéressants dans les insomnies de maintien : réflexion sur les intérêts comparés de la doxylamine et de la doxépine" [The interesting anti-H1 effects in maintenance insomnia: A reflection on the comparative advantages of doxylamine and doxepin]. Encephale (in French). 46 (1): 80–82. doi:10.1016/j.encep.2019.01.006. PMID 30879783. S2CID 151085176.
Everitt H, Baldwin DS, Stuart B, Lipinska G, Mayers A, Malizia AL, et al. (May 2018). "Antidepressants for insomnia in adults". Cochrane Database Syst Rev. 2018 (5): CD010753. doi:10.1002/14651858.CD010753.pub2. PMC 6494576. PMID 29761479.
White N, Litovitz T, Clancy C (December 2008). "Suicidal antidepressant overdoses: a comparative analysis by antidepressant type". Journal of Medical Toxicology. 4 (4): 238–50. doi:10.1007/BF03161207. PMC 3550116. PMID 19031375.
Myers B, Reddy V, Chan S, Thibodeaux Q, Brownstone N, Koo J (February 2022). "Optimizing doxepin therapy in dermatology: introducing blood level monitoring and genotype testing". The Journal of Dermatological Treatment. 33 (1): 87–93. doi:10.1080/09546634.2020.1762841. PMID 32347140. S2CID 216647836.
Krystal AD, Richelson E, Roth T (August 2013). "Review of the histamine system and the clinical effects of H1 antagonists: basis for a new model for understanding the effects of insomnia medications". Sleep Medicine Reviews. 17 (4): 263–72. doi:10.1016/j.smrv.2012.08.001. PMID 23357028.
Tatsumi M, Groshan K, Blakely RD, Richelson E (December 1997). "Pharmacological profile of antidepressants and related compounds at human monoamine transporters". European Journal of Pharmacology. 340 (2–3): 249–58. doi:10.1016/s0014-2999(97)01393-9. PMID 9537821.
Cusack B, Nelson A, Richelson E (May 1994). "Binding of antidepressants to human brain receptors: focus on newer generation compounds". Psychopharmacology. 114 (4): 559–65. doi:10.1007/bf02244985. PMID 7855217. S2CID 21236268.
Pälvimäki EP, Roth BL, Majasuo H, Laakso A, Kuoppamäki M, Syvälahti E, et al. (August 1996). "Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor". Psychopharmacology. 126 (3): 234–40. doi:10.1007/bf02246453. PMID 8876023. S2CID 24889381.
Gumilar F, Bouzat C (April 2008). "Tricyclic antidepressants inhibit homomeric Cys-loop receptors by acting at different conformational states". European Journal of Pharmacology. 584 (1): 30–9. doi:10.1016/j.ejphar.2008.01.023. hdl:11336/44466. PMID 18314100.
Appl H, Holzammer T, Dove S, Haen E, Strasser A, Seifert R (February 2012). "Interactions of recombinant human histamine H₁R, H₂R, H₃R, and H₄R receptors with 34 antidepressants and antipsychotics". Naunyn-Schmiedeberg's Archives of Pharmacology. 385 (2): 145–70. doi:10.1007/s00210-011-0704-0. PMID 22033803. S2CID 14274150.
Nguyen T, Shapiro DA, George SR, Setola V, Lee DK, Cheng R, et al. (March 2001). "Discovery of a novel member of the histamine receptor family". Molecular Pharmacology. 59 (3): 427–33. doi:10.1124/mol.59.3.427. PMID 11179435.
Stanton T, Bolden-Watson C, Cusack B, Richelson E (June 1993). "Antagonism of the five cloned human muscarinic cholinergic receptors expressed in CHO-K1 cells by antidepressants and antihistaminics". Biochemical Pharmacology. 45 (11): 2352–4. doi:10.1016/0006-2952(93)90211-e. PMID 8100134.
Duncan RS, McPate MJ, Ridley JM, Gao Z, James AF, Leishman DJ, et al. (August 2007). "Inhibition of the HERG potassium channel by the tricyclic antidepressant doxepin". Biochemical Pharmacology. 74 (3): 425–37. doi:10.1016/j.bcp.2007.04.024. PMC 1920586. PMID 17560554.
Thanacoody HK, Thomas SH (2005). "Tricyclic antidepressant poisoning : cardiovascular toxicity". Toxicological Reviews. 24 (3): 205–14. doi:10.2165/00139709-200524030-00013. PMID 16390222. S2CID 44532041.
Bertelsen AK, Backonja MM (2007). "Drugs Targeting Voltage-Gated Sodium and Calcium Channels". Encyclopedia of Pain. p. 651. doi:10.1007/978-3-540-29805-2_1205. ISBN 978-3-540-43957-8.
Singh H, Becker PM (August 2007). "Novel therapeutic usage of low-dose doxepin hydrochloride". Expert Opinion on Investigational Drugs. 16 (8): 1295–305. doi:10.1517/13543784.16.8.1295. PMID 17685877. S2CID 32810608.
Lankford A (2011). "Low-dose doxepin (3 and 6 mg) for the treatment of insomnia". Future Neurology. 6 (2): 143–154. doi:10.2217/fnl.10.83. ISSN 1479-6708.
Rojas-Fernandez CH, Chen Y (September 2014). "Use of ultra-low-dose (≤6 mg) doxepin for treatment of insomnia in older people". Canadian Pharmacists Journal. 147 (5): 281–9. doi:10.1177/1715163514543856. PMC 4213269. PMID 25364337.
Gillman PK (July 2007). "Tricyclic antidepressant pharmacology and therapeutic drug interactions updated". British Journal of Pharmacology. 151 (6): 737–48. doi:10.1038/sj.bjp.0707253. PMC 2014120. PMID 17471183.
Tariq SH, Pulisetty S (February 2008). "Pharmacotherapy for insomnia". Clinics in Geriatric Medicine. 24 (1): 93–105, vii. doi:10.1016/j.cger.2007.08.009. PMID 18035234.
Stahl SM (December 2008). "Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines". CNS Spectrums. 13 (12): 1027–38. doi:10.1017/s1092852900017089. PMID 19179941. S2CID 6849261.
Stahl SM (February 2009). "Multifunctional drugs: a novel concept for psychopharmacology". CNS Spectrums. 14 (2): 71–3. doi:10.1017/s1092852900000213. PMID 19238121. S2CID 2587534.
Vande Griend JP, Anderson SL (2012). "Histamine-1 receptor antagonism for treatment of insomnia". Journal of the American Pharmacists Association. 52 (6): e210-9. doi:10.1331/JAPhA.2012.12051. PMID 23229983.
Mets MA, van Deventer KR, Olivier B, Verster JC (2013). "Critical appraisal of ramelteon in the treatment of insomnia". Nature and Science of Sleep. 2 (4): 257–66. doi:10.1016/S2222-1808(13)60080-8. PMC 4027305. In general, sedating properties of anti-depressant agents are related to antagonism of serotonin 5HT2, histamines, and α-1 adrenergic receptors[14]–[16].
Landolt HP, Wehrle R (May 2009). "Antagonism of serotonergic 5-HT2A/2C receptors: mutual improvement of sleep, cognition and mood?". The European Journal of Neuroscience. 29 (9): 1795–809. doi:10.1111/j.1460-9568.2009.06718.x. PMID 19473234. S2CID 17097545.
Broese M, Riemann D, Hein L, Nissen C (September 2012). "α-Adrenergic receptor function, arousal and sleep: mechanisms and therapeutic implications". Pharmacopsychiatry. 45 (6): 209–16. doi:10.1055/s-0031-1299728. PMID 22290201. S2CID 28763568.
Leucht S, Steimer W, Kreuz S, Abraham D, Orsulak PJ, Kissling W (August 2001). "Doxepin plasma concentrations: is there really a therapeutic range?". Journal of Clinical Psychopharmacology. 21 (4): 432–9. doi:10.1097/00004714-200108000-00011. PMID 11476128. S2CID 32147467.
Virtanen R, Iisalo E, Irjala K (August 1982). "Protein binding of doxepin and desmethyldoxepin". Acta Pharmacologica et Toxicologica. 51 (2): 159–64. doi:10.1111/j.1600-0773.1982.tb01008.x. PMID 7113722.
Kirchheiner J, Meineke I, Müller G, Roots I, Brockmöller J (October 2002). "Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers". Pharmacogenetics. 12 (7): 571–80. doi:10.1097/00008571-200210000-00010. PMID 12360109.
Härtter S, Tybring G, Friedberg T, Weigmann H, Hiemke C (July 2002). "The N-demethylation of the doxepin isomers is mainly catalyzed by the polymorphic CYP2C19". Pharmaceutical Research. 19 (7): 1034–7. doi:10.1023/a:1016478708902. PMID 12180536. S2CID 8089917.
Kirchheiner J, Henckel HB, Franke L, Meineke I, Tzvetkov M, Uebelhack R, et al. (August 2005). "Impact of the CYP2D6 ultra-rapid metabolizer genotype on doxepin pharmacokinetics and serotonin in platelets". Pharmacogenetics and Genomics. 15 (8): 579–87. doi:10.1097/01.fpc.0000167331.30905.9e. PMID 16007002. S2CID 41765748.
Adis Editorial (1971). "Doxepin". Drugs. 1 (3): 194–227. doi:10.2165/00003495-197101030-00002. S2CID 46963857.
Casale R, Symeonidou Z, Bartolo M (March 2017). "Topical Treatments for Localized Neuropathic Pain". Current Pain and Headache Reports. 21 (3): 15. doi:10.1007/s11916-017-0615-y. PMC 5340828. PMID 28271334.

drugs.com

"International brands of doxepin". Drugs.com. Retrieved 25 October 2017.
"Doxepin Hydrochloride". Drugs.com. American Society of Health-System Pharmacists. Retrieved 20 March 2019.
"Doxepin Use During Pregnancy". Drugs.com. Retrieved 21 March 2019.

fda.gov

"Competitive Generic Therapy Approvals". U.S. Food and Drug Administration (FDA). 29 June 2023. Archived from the original on 29 June 2023. Retrieved 29 June 2023.
"First Generic Drug Approvals 2023". U.S. Food and Drug Administration (FDA). 30 May 2023. Archived from the original on 30 June 2023. Retrieved 30 June 2023.
"Sleep Disorder (Sedative-Hypnotic) Drug Information - U.S. FDA". Food and Drug Administration. 13 June 2017. Retrieved 9 August 2017.

accessdata.fda.gov

"Silenor (doxepin) label" (PDF). FDA. 17 March 2010. Retrieved 25 October 2017. For label updates see FDA index page for NDA 022036
"Doxepin hydrochloride cream" (PDF). FDA. 20 December 2002. Retrieved 25 October 2017. For label updates see FDA index page for NDA 020126

handle.net

hdl.handle.net

De Crescenzo F, D'Alò GL, Ostinelli EG, Ciabattini M, Di Franco V, Watanabe N, et al. (July 2022). "Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis". Lancet. 400 (10347): 170–184. doi:10.1016/S0140-6736(22)00878-9. hdl:11380/1288245. PMID 35843245. S2CID 250536370.
Gumilar F, Bouzat C (April 2008). "Tricyclic antidepressants inhibit homomeric Cys-loop receptors by acting at different conformational states". European Journal of Pharmacology. 584 (1): 30–9. doi:10.1016/j.ejphar.2008.01.023. hdl:11336/44466. PMID 18314100.

in.gov.br

Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 16 August 2023.

medicines.org.uk

"Sinepin Capsules 25mg - Summary of Product Characteristics (SPC)". UK Electronic Medicines Compendium. 22 January 2014. Retrieved 24 October 2017.

medicinescomplete.com

"Doxepin Hydrochloride". Martindale: The Complete Drug Reference. London, UK: Pharmaceutical Press. 30 January 2013. Retrieved 3 December 2013.

medscape.com

reference.medscape.com

"Silenor (doxepin) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 3 December 2013.

nih.gov

pubmed.ncbi.nlm.nih.gov

Yan JH, Hubbard JW, McKay G, Korchinski ED, Midha KK (July 2002). "Absolute bioavailability and stereoselective pharmacokinetics of doxepin". Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 32 (7): 615–23. doi:10.1080/00498250210131879. PMID 12162857. S2CID 7400543.
Weber J, Siddiqui MA, Wagstaff AJ, McCormack PL (August 2010). "Low-dose doxepin: in the treatment of insomnia". CNS Drugs. 24 (8): 713–20. doi:10.2165/11200810-000000000-00000. PMID 20658801. S2CID 26739281.
Virtanen R, Scheinin M, Iisalo E (November 1980). "Single dose pharmacokinetics of doxepin in healthy volunteers". Acta Pharmacologica et Toxicologica. 47 (5): 371–6. doi:10.1111/j.1600-0773.1980.tb01575.x. PMID 7293791.
Yeung WF, Chung KF, Yung KP, Ng TH (February 2015). "Doxepin for insomnia: a systematic review of randomized placebo-controlled trials". Sleep Medicine Reviews. 19: 75–83. doi:10.1016/j.smrv.2014.06.001. PMID 25047681.
Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL (February 2017). "Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline". Journal of Clinical Sleep Medicine. 13 (2): 307–349. doi:10.5664/jcsm.6470. PMC 5263087. PMID 27998379.
Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD (July 2016). "Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians". Annals of Internal Medicine. 165 (2): 125–33. doi:10.7326/M15-2175. PMID 27136449.
Brasure M, MacDonald R, Fuchs E, Olson CM, Carlyle M, Diem S, et al. (2015). "Management of Insomnia Disorder: Executive Summary". Agency for Healthcare Research and Quality Report No. 15(16)-EHC027-EF. AHRQ Comparative Effectiveness Reviews. Agency for Healthcare Research and Quality (US). PMID 26844312.
De Crescenzo F, D'Alò GL, Ostinelli EG, Ciabattini M, Di Franco V, Watanabe N, et al. (July 2022). "Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis". Lancet. 400 (10347): 170–184. doi:10.1016/S0140-6736(22)00878-9. hdl:11380/1288245. PMID 35843245. S2CID 250536370.
Dupuis G, Vaugeois JM (February 2020). "Les effets anti-H1 intéressants dans les insomnies de maintien : réflexion sur les intérêts comparés de la doxylamine et de la doxépine" [The interesting anti-H1 effects in maintenance insomnia: A reflection on the comparative advantages of doxylamine and doxepin]. Encephale (in French). 46 (1): 80–82. doi:10.1016/j.encep.2019.01.006. PMID 30879783. S2CID 151085176.
Everitt H, Baldwin DS, Stuart B, Lipinska G, Mayers A, Malizia AL, et al. (May 2018). "Antidepressants for insomnia in adults". Cochrane Database Syst Rev. 2018 (5): CD010753. doi:10.1002/14651858.CD010753.pub2. PMC 6494576. PMID 29761479.
Eschler DC, Klein PA (August 2010). "An evidence-based review of the efficacy of topical antihistamines in the relief of pruritus". Journal of Drugs in Dermatology. 9 (8): 992–7. PMID 20684150.
Fernando S, Broadfoot A (March 2010). "Chronic urticaria--assessment and treatment" (PDF). Australian Family Physician. 39 (3): 135–8. PMID 20369115. Archived from the original (PDF) on 24 November 2018. Retrieved 25 October 2017.
White N, Litovitz T, Clancy C (December 2008). "Suicidal antidepressant overdoses: a comparative analysis by antidepressant type". Journal of Medical Toxicology. 4 (4): 238–50. doi:10.1007/BF03161207. PMC 3550116. PMID 19031375.
Myers B, Reddy V, Chan S, Thibodeaux Q, Brownstone N, Koo J (February 2022). "Optimizing doxepin therapy in dermatology: introducing blood level monitoring and genotype testing". The Journal of Dermatological Treatment. 33 (1): 87–93. doi:10.1080/09546634.2020.1762841. PMID 32347140. S2CID 216647836.
Krystal AD, Richelson E, Roth T (August 2013). "Review of the histamine system and the clinical effects of H1 antagonists: basis for a new model for understanding the effects of insomnia medications". Sleep Medicine Reviews. 17 (4): 263–72. doi:10.1016/j.smrv.2012.08.001. PMID 23357028.
Tatsumi M, Groshan K, Blakely RD, Richelson E (December 1997). "Pharmacological profile of antidepressants and related compounds at human monoamine transporters". European Journal of Pharmacology. 340 (2–3): 249–58. doi:10.1016/s0014-2999(97)01393-9. PMID 9537821.
Cusack B, Nelson A, Richelson E (May 1994). "Binding of antidepressants to human brain receptors: focus on newer generation compounds". Psychopharmacology. 114 (4): 559–65. doi:10.1007/bf02244985. PMID 7855217. S2CID 21236268.
Pälvimäki EP, Roth BL, Majasuo H, Laakso A, Kuoppamäki M, Syvälahti E, et al. (August 1996). "Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor". Psychopharmacology. 126 (3): 234–40. doi:10.1007/bf02246453. PMID 8876023. S2CID 24889381.
Gumilar F, Bouzat C (April 2008). "Tricyclic antidepressants inhibit homomeric Cys-loop receptors by acting at different conformational states". European Journal of Pharmacology. 584 (1): 30–9. doi:10.1016/j.ejphar.2008.01.023. hdl:11336/44466. PMID 18314100.
Monsma FJ, Shen Y, Ward RP, Hamblin MW, Sibley DR (March 1993). "Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs". Molecular Pharmacology. 43 (3): 320–7. PMID 7680751.
Appl H, Holzammer T, Dove S, Haen E, Strasser A, Seifert R (February 2012). "Interactions of recombinant human histamine H₁R, H₂R, H₃R, and H₄R receptors with 34 antidepressants and antipsychotics". Naunyn-Schmiedeberg's Archives of Pharmacology. 385 (2): 145–70. doi:10.1007/s00210-011-0704-0. PMID 22033803. S2CID 14274150.
Nguyen T, Shapiro DA, George SR, Setola V, Lee DK, Cheng R, et al. (March 2001). "Discovery of a novel member of the histamine receptor family". Molecular Pharmacology. 59 (3): 427–33. doi:10.1124/mol.59.3.427. PMID 11179435.
Richelson E, Nelson A (July 1984). "Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro". The Journal of Pharmacology and Experimental Therapeutics. 230 (1): 94–102. PMID 6086881.
Stanton T, Bolden-Watson C, Cusack B, Richelson E (June 1993). "Antagonism of the five cloned human muscarinic cholinergic receptors expressed in CHO-K1 cells by antidepressants and antihistaminics". Biochemical Pharmacology. 45 (11): 2352–4. doi:10.1016/0006-2952(93)90211-e. PMID 8100134.
Duncan RS, McPate MJ, Ridley JM, Gao Z, James AF, Leishman DJ, et al. (August 2007). "Inhibition of the HERG potassium channel by the tricyclic antidepressant doxepin". Biochemical Pharmacology. 74 (3): 425–37. doi:10.1016/j.bcp.2007.04.024. PMC 1920586. PMID 17560554.
Thanacoody HK, Thomas SH (2005). "Tricyclic antidepressant poisoning : cardiovascular toxicity". Toxicological Reviews. 24 (3): 205–14. doi:10.2165/00139709-200524030-00013. PMID 16390222. S2CID 44532041.
Singh H, Becker PM (August 2007). "Novel therapeutic usage of low-dose doxepin hydrochloride". Expert Opinion on Investigational Drugs. 16 (8): 1295–305. doi:10.1517/13543784.16.8.1295. PMID 17685877. S2CID 32810608.
Rojas-Fernandez CH, Chen Y (September 2014). "Use of ultra-low-dose (≤6 mg) doxepin for treatment of insomnia in older people". Canadian Pharmacists Journal. 147 (5): 281–9. doi:10.1177/1715163514543856. PMC 4213269. PMID 25364337.
Gillman PK (July 2007). "Tricyclic antidepressant pharmacology and therapeutic drug interactions updated". British Journal of Pharmacology. 151 (6): 737–48. doi:10.1038/sj.bjp.0707253. PMC 2014120. PMID 17471183.
Tariq SH, Pulisetty S (February 2008). "Pharmacotherapy for insomnia". Clinics in Geriatric Medicine. 24 (1): 93–105, vii. doi:10.1016/j.cger.2007.08.009. PMID 18035234.
Stahl SM (December 2008). "Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines". CNS Spectrums. 13 (12): 1027–38. doi:10.1017/s1092852900017089. PMID 19179941. S2CID 6849261.
Richelson E (October 1979). "Tricyclic antidepressants and histamine H1 receptors". Mayo Clinic Proceedings. 54 (10): 669–74. PMID 39202.
Stahl SM (February 2009). "Multifunctional drugs: a novel concept for psychopharmacology". CNS Spectrums. 14 (2): 71–3. doi:10.1017/s1092852900000213. PMID 19238121. S2CID 2587534.
Vande Griend JP, Anderson SL (2012). "Histamine-1 receptor antagonism for treatment of insomnia". Journal of the American Pharmacists Association. 52 (6): e210-9. doi:10.1331/JAPhA.2012.12051. PMID 23229983.
Landolt HP, Wehrle R (May 2009). "Antagonism of serotonergic 5-HT2A/2C receptors: mutual improvement of sleep, cognition and mood?". The European Journal of Neuroscience. 29 (9): 1795–809. doi:10.1111/j.1460-9568.2009.06718.x. PMID 19473234. S2CID 17097545.
Broese M, Riemann D, Hein L, Nissen C (September 2012). "α-Adrenergic receptor function, arousal and sleep: mechanisms and therapeutic implications". Pharmacopsychiatry. 45 (6): 209–16. doi:10.1055/s-0031-1299728. PMID 22290201. S2CID 28763568.
Szewczuk-Bogusławska M, Kiejna A, Beszłej JA, Orzechowska-Juzwenko K, Milejski P (2004). "Doxepin inhibits CYP2D6 activity in vivo". Polish Journal of Pharmacology. 56 (4): 491–4. PMID 15520506.
Leucht S, Steimer W, Kreuz S, Abraham D, Orsulak PJ, Kissling W (August 2001). "Doxepin plasma concentrations: is there really a therapeutic range?". Journal of Clinical Psychopharmacology. 21 (4): 432–9. doi:10.1097/00004714-200108000-00011. PMID 11476128. S2CID 32147467.
Virtanen R, Iisalo E, Irjala K (August 1982). "Protein binding of doxepin and desmethyldoxepin". Acta Pharmacologica et Toxicologica. 51 (2): 159–64. doi:10.1111/j.1600-0773.1982.tb01008.x. PMID 7113722.
Kirchheiner J, Meineke I, Müller G, Roots I, Brockmöller J (October 2002). "Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers". Pharmacogenetics. 12 (7): 571–80. doi:10.1097/00008571-200210000-00010. PMID 12360109.
Härtter S, Tybring G, Friedberg T, Weigmann H, Hiemke C (July 2002). "The N-demethylation of the doxepin isomers is mainly catalyzed by the polymorphic CYP2C19". Pharmaceutical Research. 19 (7): 1034–7. doi:10.1023/a:1016478708902. PMID 12180536. S2CID 8089917.
Kirchheiner J, Henckel HB, Franke L, Meineke I, Tzvetkov M, Uebelhack R, et al. (August 2005). "Impact of the CYP2D6 ultra-rapid metabolizer genotype on doxepin pharmacokinetics and serotonin in platelets". Pharmacogenetics and Genomics. 15 (8): 579–87. doi:10.1097/01.fpc.0000167331.30905.9e. PMID 16007002. S2CID 41765748.
Casale R, Symeonidou Z, Bartolo M (March 2017). "Topical Treatments for Localized Neuropathic Pain". Current Pain and Headache Reports. 21 (3): 15. doi:10.1007/s11916-017-0615-y. PMC 5340828. PMID 28271334.

ncbi.nlm.nih.gov

Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL (February 2017). "Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline". Journal of Clinical Sleep Medicine. 13 (2): 307–349. doi:10.5664/jcsm.6470. PMC 5263087. PMID 27998379.
Brasure M, MacDonald R, Fuchs E, Olson CM, Carlyle M, Diem S, et al. (2015). "Management of Insomnia Disorder: Executive Summary". Agency for Healthcare Research and Quality Report No. 15(16)-EHC027-EF. AHRQ Comparative Effectiveness Reviews. Agency for Healthcare Research and Quality (US). PMID 26844312.
Everitt H, Baldwin DS, Stuart B, Lipinska G, Mayers A, Malizia AL, et al. (May 2018). "Antidepressants for insomnia in adults". Cochrane Database Syst Rev. 2018 (5): CD010753. doi:10.1002/14651858.CD010753.pub2. PMC 6494576. PMID 29761479.
White N, Litovitz T, Clancy C (December 2008). "Suicidal antidepressant overdoses: a comparative analysis by antidepressant type". Journal of Medical Toxicology. 4 (4): 238–50. doi:10.1007/BF03161207. PMC 3550116. PMID 19031375.
Duncan RS, McPate MJ, Ridley JM, Gao Z, James AF, Leishman DJ, et al. (August 2007). "Inhibition of the HERG potassium channel by the tricyclic antidepressant doxepin". Biochemical Pharmacology. 74 (3): 425–37. doi:10.1016/j.bcp.2007.04.024. PMC 1920586. PMID 17560554.
Rojas-Fernandez CH, Chen Y (September 2014). "Use of ultra-low-dose (≤6 mg) doxepin for treatment of insomnia in older people". Canadian Pharmacists Journal. 147 (5): 281–9. doi:10.1177/1715163514543856. PMC 4213269. PMID 25364337.
Gillman PK (July 2007). "Tricyclic antidepressant pharmacology and therapeutic drug interactions updated". British Journal of Pharmacology. 151 (6): 737–48. doi:10.1038/sj.bjp.0707253. PMC 2014120. PMID 17471183.
Mets MA, van Deventer KR, Olivier B, Verster JC (2013). "Critical appraisal of ramelteon in the treatment of insomnia". Nature and Science of Sleep. 2 (4): 257–66. doi:10.1016/S2222-1808(13)60080-8. PMC 4027305. In general, sedating properties of anti-depressant agents are related to antagonism of serotonin 5HT2, histamines, and α-1 adrenergic receptors[14]–[16].
Casale R, Symeonidou Z, Bartolo M (March 2017). "Topical Treatments for Localized Neuropathic Pain". Current Pain and Headache Reports. 21 (3): 15. doi:10.1007/s11916-017-0615-y. PMC 5340828. PMID 28271334.

chem.nlm.nih.gov

Chambers M. "Doxepin [INN:BAN] - Similar structures search, synonyms, formulas, resource links, and other chemical information". ChemIDplus. U.S. National Library of Medicine. Retrieved 16 March 2019.

dailymed.nlm.nih.gov

"PRUDOXIN (doxepin hydrochloride) cream". DailyMed. August 2010. Retrieved 3 December 2013.

racgp.org.au

Fernando S, Broadfoot A (March 2010). "Chronic urticaria--assessment and treatment" (PDF). Australian Family Physician. 39 (3): 135–8. PMID 20369115. Archived from the original (PDF) on 24 November 2018. Retrieved 25 October 2017.

semanticscholar.org

api.semanticscholar.org

Yan JH, Hubbard JW, McKay G, Korchinski ED, Midha KK (July 2002). "Absolute bioavailability and stereoselective pharmacokinetics of doxepin". Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 32 (7): 615–23. doi:10.1080/00498250210131879. PMID 12162857. S2CID 7400543.
Weber J, Siddiqui MA, Wagstaff AJ, McCormack PL (August 2010). "Low-dose doxepin: in the treatment of insomnia". CNS Drugs. 24 (8): 713–20. doi:10.2165/11200810-000000000-00000. PMID 20658801. S2CID 26739281.
De Crescenzo F, D'Alò GL, Ostinelli EG, Ciabattini M, Di Franco V, Watanabe N, et al. (July 2022). "Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis". Lancet. 400 (10347): 170–184. doi:10.1016/S0140-6736(22)00878-9. hdl:11380/1288245. PMID 35843245. S2CID 250536370.
Dupuis G, Vaugeois JM (February 2020). "Les effets anti-H1 intéressants dans les insomnies de maintien : réflexion sur les intérêts comparés de la doxylamine et de la doxépine" [The interesting anti-H1 effects in maintenance insomnia: A reflection on the comparative advantages of doxylamine and doxepin]. Encephale (in French). 46 (1): 80–82. doi:10.1016/j.encep.2019.01.006. PMID 30879783. S2CID 151085176.
Myers B, Reddy V, Chan S, Thibodeaux Q, Brownstone N, Koo J (February 2022). "Optimizing doxepin therapy in dermatology: introducing blood level monitoring and genotype testing". The Journal of Dermatological Treatment. 33 (1): 87–93. doi:10.1080/09546634.2020.1762841. PMID 32347140. S2CID 216647836.
Cusack B, Nelson A, Richelson E (May 1994). "Binding of antidepressants to human brain receptors: focus on newer generation compounds". Psychopharmacology. 114 (4): 559–65. doi:10.1007/bf02244985. PMID 7855217. S2CID 21236268.
Pälvimäki EP, Roth BL, Majasuo H, Laakso A, Kuoppamäki M, Syvälahti E, et al. (August 1996). "Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor". Psychopharmacology. 126 (3): 234–40. doi:10.1007/bf02246453. PMID 8876023. S2CID 24889381.
Appl H, Holzammer T, Dove S, Haen E, Strasser A, Seifert R (February 2012). "Interactions of recombinant human histamine H₁R, H₂R, H₃R, and H₄R receptors with 34 antidepressants and antipsychotics". Naunyn-Schmiedeberg's Archives of Pharmacology. 385 (2): 145–70. doi:10.1007/s00210-011-0704-0. PMID 22033803. S2CID 14274150.
Thanacoody HK, Thomas SH (2005). "Tricyclic antidepressant poisoning : cardiovascular toxicity". Toxicological Reviews. 24 (3): 205–14. doi:10.2165/00139709-200524030-00013. PMID 16390222. S2CID 44532041.
Singh H, Becker PM (August 2007). "Novel therapeutic usage of low-dose doxepin hydrochloride". Expert Opinion on Investigational Drugs. 16 (8): 1295–305. doi:10.1517/13543784.16.8.1295. PMID 17685877. S2CID 32810608.
Stahl SM (December 2008). "Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines". CNS Spectrums. 13 (12): 1027–38. doi:10.1017/s1092852900017089. PMID 19179941. S2CID 6849261.
Stahl SM (February 2009). "Multifunctional drugs: a novel concept for psychopharmacology". CNS Spectrums. 14 (2): 71–3. doi:10.1017/s1092852900000213. PMID 19238121. S2CID 2587534.
Landolt HP, Wehrle R (May 2009). "Antagonism of serotonergic 5-HT2A/2C receptors: mutual improvement of sleep, cognition and mood?". The European Journal of Neuroscience. 29 (9): 1795–809. doi:10.1111/j.1460-9568.2009.06718.x. PMID 19473234. S2CID 17097545.
Broese M, Riemann D, Hein L, Nissen C (September 2012). "α-Adrenergic receptor function, arousal and sleep: mechanisms and therapeutic implications". Pharmacopsychiatry. 45 (6): 209–16. doi:10.1055/s-0031-1299728. PMID 22290201. S2CID 28763568.
Leucht S, Steimer W, Kreuz S, Abraham D, Orsulak PJ, Kissling W (August 2001). "Doxepin plasma concentrations: is there really a therapeutic range?". Journal of Clinical Psychopharmacology. 21 (4): 432–9. doi:10.1097/00004714-200108000-00011. PMID 11476128. S2CID 32147467.
Härtter S, Tybring G, Friedberg T, Weigmann H, Hiemke C (July 2002). "The N-demethylation of the doxepin isomers is mainly catalyzed by the polymorphic CYP2C19". Pharmaceutical Research. 19 (7): 1034–7. doi:10.1023/a:1016478708902. PMID 12180536. S2CID 8089917.
Kirchheiner J, Henckel HB, Franke L, Meineke I, Tzvetkov M, Uebelhack R, et al. (August 2005). "Impact of the CYP2D6 ultra-rapid metabolizer genotype on doxepin pharmacokinetics and serotonin in platelets". Pharmacogenetics and Genomics. 15 (8): 579–87. doi:10.1097/01.fpc.0000167331.30905.9e. PMID 16007002. S2CID 41765748.
Adis Editorial (1971). "Doxepin". Drugs. 1 (3): 194–227. doi:10.2165/00003495-197101030-00002. S2CID 46963857.

springer.com

adisinsight.springer.com

"Cidoxepin". Adisinsight.springer.com. Retrieved 16 March 2019.
"Doxepin intranasal - Winston Pharmaceuticals". Adisinsight.springer.com. Retrieved 16 March 2019.

tga.gov.au

ebs.tga.gov.au

"Deptran Doxepin (as hydrochloride)" (PDF). TGA eBusiness Services. Alphapharm Pty Ltd. 6 May 2013. Retrieved 3 December 2013.

unc.edu

kidbdev.med.unc.edu

Roth BL, Driscol J. "PDSP K_i Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Retrieved 14 August 2017.

cdr.lib.unc.edu

Nguyen T, Shapiro DA, George SR, Setola V, Lee DK, Cheng R, et al. (March 2001). "Discovery of a novel member of the histamine receptor family". Molecular Pharmacology. 59 (3): 427–33. doi:10.1124/mol.59.3.427. PMID 11179435.

web.archive.org

Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 16 August 2023.
"Competitive Generic Therapy Approvals". U.S. Food and Drug Administration (FDA). 29 June 2023. Archived from the original on 29 June 2023. Retrieved 29 June 2023.
"First Generic Drug Approvals 2023". U.S. Food and Drug Administration (FDA). 30 May 2023. Archived from the original on 30 June 2023. Retrieved 30 June 2023.
"The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
Fernando S, Broadfoot A (March 2010). "Chronic urticaria--assessment and treatment" (PDF). Australian Family Physician. 39 (3): 135–8. PMID 20369115. Archived from the original (PDF) on 24 November 2018. Retrieved 25 October 2017.

worldcat.org

search.worldcat.org

Lankford A (2011). "Low-dose doxepin (3 and 6 mg) for the treatment of insomnia". Future Neurology. 6 (2): 143–154. doi:10.2217/fnl.10.83. ISSN 1479-6708.